NASDAQ:MIST

Milestone Pharmaceuticals Q1 2025 Earnings Report

Milestone Pharmaceuticals logo
$1.27 -0.03 (-2.31%)
Closing price 06/24/2026 04:00 PM Eastern
Extended Trading
$1.28 +0.01 (+1.10%)
As of 06/24/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Milestone Pharmaceuticals EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.19
Beat/Miss
Missed by -$0.12
One Year Ago EPS
N/A

Milestone Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Milestone Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Milestone Pharmaceuticals' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 10, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Milestone Pharmaceuticals Earnings Headlines

Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
Milestone Pharmaceuticals: Taking The Long View
See More Milestone Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Milestone Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Milestone Pharmaceuticals and other key companies, straight to your email.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals (NASDAQ:MIST), Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs. Preclinical and early clinical studies are aimed at demonstrating safety, tolerability and proof of concept in patient populations with high unmet medical need. The company leverages strategic collaborations and research partnerships to accelerate development and expand its scientific expertise.

Founded in the United States and headquartered in San Diego, California, Milestone Pharmaceuticals operates with a management team experienced in respiratory drug development. The company continues to pursue regulatory pathways for its lead programs and is preparing for later-stage clinical trials. Through a combination of internal innovation and external partnerships, Milestone seeks to bring new treatment options to patients suffering from debilitating respiratory disorders.

View Milestone Pharmaceuticals Profile